Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences (PCRX) Form 144: The filer notifies a proposed sale of 2,354 shares of common stock acquired on 06/12/2025 upon restricted stock vesting. The shares are to be sold through Fidelity Brokerage Services LLC with an approximate aggregate market value of $64,005.26 and an indicated approximate sale date of 09/04/2025. The filing reports 44,932,721 shares outstanding for the issuer. No securities were reported sold in the prior three months. The filer represents they are unaware of undisclosed material adverse information.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported beneficial ownership of 2,395,601 shares of Pacira BioSciences common stock, representing 5.34% of the outstanding class. The filing states the reporting persons have sole voting and sole dispositive power over these shares. It also notes that certain funds managed by Renaissance have the right to receive dividends and proceeds from the sale of the securities. The statement certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
This disclosure crosses the 5% reporting threshold and provides clarity on who controls the position without indicating an activist intent.
Pacira BioSciences director Bigal Marcelo reported a sale of 4,912 shares of common stock at $23.67 per share on 08/07/2025, reducing his direct holding to 11,393 shares. The Form 4 discloses no derivative transactions. The filing documents an insider sale and the remaining direct beneficial ownership reported by the director.
This Schedule 13D discloses that Doma Perpetual-related entities, Pedro Escudero and the John Templeton Foundation together beneficially own 2,698,618 common shares of Pacira BioSciences, representing 5.7% of 47,432,721 outstanding shares as of 8/5/2025. Doma Master Fund accumulated 1,804,069 shares in 2023–Q1 2025 for an aggregate purchase price of $48,257,894; Mr. Escudero bought 159,000 shares in Q3 2024 for $3,256,514; the John Templeton Foundation purchased 735,549 shares on 8/1, 8/4 and 8/5/2025 for $16,329,100.
The reporting persons state the shares were acquired "with the intent to influence the Issuer" but not to take full control. They say they are not currently pursuing a merger, management or operational changes, though they may contemplate such actions if the Common Shares are deemed to be underperforming. The filing includes no contracts or exhibits describing specific plans.
Pacira BioSciences (PCRX) filed an 8-K on 9 July 2025 announcing a restructuring under Item 2.05. The company is shuttering its first-generation 45-liter manufacturing suite at its San Diego Science Center after commissioning two 200-plus-liter suites (Swindon 2021, San Diego 2024) that produce roughly 4× more bulk EXPAREL per batch and carry a lower cost structure.
The decision triggers a reduction in force of 71 employees, or ~8 % of head-count. Management expects to book $2.4 – $2.8 million in cash charges for severance, garden leave and related benefits plus $5.4 million of accelerated depreciation, with most of the impact flowing through Q3 2025 results.
Once complete, Pacira anticipates an annual operating-expense reduction of about $13 million and improved gross margins for EXPAREL owing to higher yields and scale efficiencies. The company cautions that additional, presently unforeseen, charges may arise and reiterates standard forward-looking-statement language.
An employee communication from CEO Frank D. Lee (Exhibit 99.1) was furnished under Item 7.01 and is not deemed filed. No changes were disclosed to current revenue guidance, product strategy or other financial metrics beyond the charges and cost-saving estimates.